These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 30909527

  • 21. Bioactive fraction of Rhodiola algida against chronic hypoxia-induced pulmonary arterial hypertension and its anti-proliferation mechanism in rats.
    Nan X, Su S, Ma K, Ma X, Wang X, Zhaxi D, Ge R, Li Z, Lu D.
    J Ethnopharmacol; 2018 Apr 24; 216():175-183. PubMed ID: 29325918
    [Abstract] [Full Text] [Related]

  • 22. Combined hypoxia inducible factor-1α and homogeneous endothelial progenitor cell therapy attenuates shunt flow-induced pulmonary arterial hypertension in rabbits.
    Cao G, Liu C, Wan Z, Liu K, Sun H, Sun X, Tang M, Bing W, Wu S, Pang X, Zhang X.
    J Thorac Cardiovasc Surg; 2015 Sep 24; 150(3):621-32. PubMed ID: 26071969
    [Abstract] [Full Text] [Related]

  • 23. Implication of PDGF signaling in cigarette smoke-induced pulmonary arterial hypertension in rat.
    Xing AP, Hu XY, Shi YW, Du YC.
    Inhal Toxicol; 2012 Jul 24; 24(8):468-75. PubMed ID: 22746397
    [Abstract] [Full Text] [Related]

  • 24. Caffeic acid phenethyl ester inhibits PDGF-induced proliferation of vascular smooth muscle cells via activation of p38 MAPK, HIF-1α, and heme oxygenase-1.
    Roos TU, Heiss EH, Schwaiberger AV, Schachner D, Sroka IM, Oberan T, Vollmar AM, Dirsch VM.
    J Nat Prod; 2011 Mar 25; 74(3):352-6. PubMed ID: 21265554
    [Abstract] [Full Text] [Related]

  • 25. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C, Shi W, Feng W, Zhu Y, Wang J, Li S, Yan X, Wang Q, Zhang Q, Chai L, Li C, Liu P, Li M.
    Life Sci; 2018 Sep 01; 208():87-95. PubMed ID: 30009823
    [Abstract] [Full Text] [Related]

  • 26. Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
    Behringer A, Trappiel M, Berghausen EM, Ten Freyhaus H, Wellnhofer E, Odenthal M, Blaschke F, Er F, Gassanov N, Rosenkranz S, Baldus S, Kappert K, Caglayan E.
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr 01; 389(4):369-79. PubMed ID: 26742933
    [Abstract] [Full Text] [Related]

  • 27. Canagliflozin inhibits PASMCs proliferation via regulating SGLT1/AMPK signaling and attenuates artery remodeling in MCT-induced pulmonary arterial hypertension.
    Chen X, Yu X, Lian G, Tang H, Yan Y, Gao G, Huang B, Luo L, Xie L.
    Biomed Pharmacother; 2024 May 01; 174():116505. PubMed ID: 38574614
    [Abstract] [Full Text] [Related]

  • 28. PAR-2 inhibition reverses experimental pulmonary hypertension.
    Kwapiszewska G, Markart P, Dahal BK, Kojonazarov B, Marsh LM, Schermuly RT, Taube C, Meinhardt A, Ghofrani HA, Steinhoff M, Seeger W, Preissner KT, Olschewski A, Weissmann N, Wygrecka M.
    Circ Res; 2012 Apr 27; 110(9):1179-91. PubMed ID: 22461388
    [Abstract] [Full Text] [Related]

  • 29. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
    Yang PS, Kim DH, Lee YJ, Lee SE, Kang WJ, Chang HJ, Shin JS.
    Respir Res; 2014 Nov 25; 15():148. PubMed ID: 25420924
    [Abstract] [Full Text] [Related]

  • 30. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
    Shi R, Wei Z, Zhu D, Fu N, Wang C, Yin S, Liang Y, Xing J, Wang X, Wang Y.
    Pulm Pharmacol Ther; 2018 Feb 25; 48():124-135. PubMed ID: 29133079
    [Abstract] [Full Text] [Related]

  • 31. Quercetin reverses experimental pulmonary arterial hypertension by modulating the TrkA pathway.
    He Y, Cao X, Liu X, Li X, Xu Y, Liu J, Shi J.
    Exp Cell Res; 2015 Nov 15; 339(1):122-34. PubMed ID: 26476374
    [Abstract] [Full Text] [Related]

  • 32. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N, Satoh K, Kurosawa R, Yaoita N, Elias-Al-Mamun M, Siddique MAH, Omura J, Satoh T, Nogi M, Sunamura S, Miyata S, Saito Y, Hoshikawa Y, Okada Y, Shimokawa H.
    Circulation; 2018 Aug 07; 138(6):600-623. PubMed ID: 29636330
    [Abstract] [Full Text] [Related]

  • 33. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q, Wang J, Zhu X, Zeng Z, Wu X, Xu Y, Xie J, Yu J.
    Biomed Pharmacother; 2017 Dec 07; 96():825-833. PubMed ID: 29078260
    [Abstract] [Full Text] [Related]

  • 34. Unraveling the Impact of miR-146a in Pulmonary Arterial Hypertension Pathophysiology and Right Ventricular Function.
    Santos-Gomes J, Mendes-Ferreira P, Adão R, Maia-Rocha C, Rego B, Poels M, Saint-Martin Willer A, Masson B, Provencher S, Bonnet S, Montani D, Perros F, Antigny F, Leite-Moreira AF, Brás-Silva C.
    Int J Mol Sci; 2024 Jul 24; 25(15):. PubMed ID: 39125620
    [Abstract] [Full Text] [Related]

  • 35. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
    Wang X, Yang Y, Yang D, Tong G, Lv S, Lin X, Chen C, Dong W.
    J Vasc Surg; 2016 Nov 24; 64(5):1468-1477. PubMed ID: 26527422
    [Abstract] [Full Text] [Related]

  • 36. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S, Haraguchi G, Sasaki A, Arai H, Muto S, Itai A, Doi S, Mizutani S, Isobe M.
    Cardiovasc Res; 2013 Jul 01; 99(1):35-43. PubMed ID: 23631839
    [Abstract] [Full Text] [Related]

  • 37. Quercetin regulates pulmonary vascular remodeling in pulmonary hypertension by downregulating TGF-β1-Smad2/3 pathway.
    Gao RJ, Aikeremu N, Cao N, Chen C, Ma KT, Li L, Zhang AM, Si JQ.
    BMC Cardiovasc Disord; 2024 Oct 04; 24(1):535. PubMed ID: 39367342
    [Abstract] [Full Text] [Related]

  • 38. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
    Shi W, Zhai C, Feng W, Wang J, Zhu Y, Li S, Wang Q, Zhang Q, Yan X, Chai L, Liu P, Chen Y, Li M.
    Life Sci; 2018 Oct 01; 210():140-149. PubMed ID: 30179628
    [Abstract] [Full Text] [Related]

  • 39. Regulatory T cells protect against hypoxia-induced pulmonary arterial hypertension in mice.
    Chu Y, Xiangli X, Xiao W.
    Mol Med Rep; 2015 Apr 01; 11(4):3181-7. PubMed ID: 25523119
    [Abstract] [Full Text] [Related]

  • 40. Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation With Medial Thickening in Mice.
    Jiang L, Konishi H, Nurwidya F, Satoh K, Takahashi F, Ebinuma H, Fujimura K, Takasu K, Jiang M, Shimokawa H, Bujo H, Daida H.
    Arterioscler Thromb Vasc Biol; 2016 Sep 01; 36(9):1972-9. PubMed ID: 27493099
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.